ASH 2023: Exploring Therapeutic Advancements for Chronic Lymphocytic Leukemia - Episode 4

Impact of Off-Target AEs and Treatment Resistance on Evolving 1L Therapy Strategies for CLL

January 12, 2024

Catherine C. Coombs, MD, Brian T. Hill, MD, PhD, Ryan W. Jacobs, MD, Jacqueline Barrientos, MD, MS, Javier Pinilla-Ibarz, MD, PhD, Joanna M. Rhodes, MD, MSCE

Javier Pinilla, MD, PhD, provides a brief overview of the changing CLL treatment landscape, discussing the influence of off-target adverse events and the development of treatment resistance on the evolution of BTK inhibitor therapy.

EP. 1: Current Front-Line Treatment Options for CLL in 2023

EP. 2: Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA

EP. 3: Strategies for Managing Treatment-Naïve CLL with High-Risk Features

Now Viewing

EP. 4: Impact of Off-Target AEs and Treatment Resistance on Evolving 1L Therapy Strategies for CLL

EP. 5: Exploring the Role of BTKi-Based Combination Therapies for Front-line Management of CLL

EP. 6: Treatment Sequencing Strategies for R/R CLL: Impact of Prior 1L Therapy

EP. 7: Navigating BTKi Therapy in R/R CLL: Updates from ELEVATE-RR and ALPINE

EP. 8: Expert Perspectives on Navigating Treatment Selection with BTKis in CLL

EP. 9: Expert Insights into Navigating Cardiovascular Risks with BTKi Therapy

EP. 10: Treatment Resistance with Covalent BTKis: Translating Data into Clinical Practice

EP. 11: Role of Non-Covalent BTKis in R/R CLL: Updates from Ongoing BRUIN and Bellwave Trials

EP. 12: Emerging Data Surrounding Mechanisms of Resistance to Non-Covalent BTKis

EP. 13: Expert Insights into Investigation Therapies for CLL

EP. 14: Future Perspectives on the Treatment Landscape for CLL